Product Information
RIFAMPIN 300 MG CAPSULE is a generic product labeled by American Health Packaging, priced at $0.6789 per EA under NDC 60687058601. Its NADAC has been published 283 times since May 5, 2021.
FDA first approved this application on Aug 21, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
American Health PackagingNDC
60687058601
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIFAMPINApproval Type
Generic (ANDA)
FDA Application
ANDA090034FDA Approved
8/21/2013
TE Code
AB
On Market Since
3/9/2021
Pharmacological Classes
Price Statistics
The NADAC for RIFAMPIN 300 MG CAPSULE has been published 283 times since May 5, 2021, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6789 per EA |
|---|---|
| All-time high | $0.9590 (Apr 13, 2022) |
| All-time low | $0.4888 (Nov 20, 2024) |
| 52-week high | $0.7186 |
| 52-week low | $0.6789 |
| Median price | $0.6921 |
| Average price | $0.6896 |
| Largest weekly change | -29.8% (Apr 20, 2022) |
| Weeks tracked | 283 |
| Tracking since | May 5, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Rifampin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
American Health Packaging manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rifampin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Rifamycin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIFAMPIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIFAMPIN 300 MG CAPSULE, manufactured by American Health Packaging, is $0.6789 per EA (NDC 60687058601), effective Sep 30, 2026.
How has the price of RIFAMPIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIFAMPIN 300 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 283 weekly CMS publications since May 5, 2021.
What are the highest and lowest recorded NADAC prices for RIFAMPIN 300 MG CAPSULE?
Since May 5, 2021, the NADAC for RIFAMPIN 300 MG CAPSULE has ranged from a low of $0.4888 (Nov 20, 2024) to a high of $0.9590 (Apr 13, 2022), with a median of $0.6921 per EA.
Are there cheaper alternatives to RIFAMPIN 300 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of RIFAMPIN 300 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RIFAMPIN 300 MG CAPSULE?
RIFAMPIN 300 MG CAPSULE (NDC 60687058601) is labeled by American Health Packaging, and CMS classifies it as a generic product.